San Diego’s Q1 Venture Activity Surges on One Mega Deal

4/20/12Follow @bvbigelow

(Page 2 of 2)

14 percent drop in terms of dollars and a 5.4 percent decline in the number of deals compared to first quarter of 2011 when $6.7 billion was invested in 801 deals.

In a statement today, NVCA President Mark Heesen says, “The overall decline in investment in the first quarter underlies several shifts occurring in the venture space. The industry continues to contract and consolidate which is beginning to manifest itself in fewer dollars being invested in fewer deals.”

Dow Jones VentureSource said companies based throughout the United States raised $6.3 billion through 717 venture capital deals during the first quarter of 2012. That’s an 18 percent decline in capital and a 9 percent decline in deals from the same period last year.

Based on data in the MoneyTree report, San Diego’s 10 biggest first-quarter VC deals were:

Sapphire Energy, $140 million

Celladon, $42.2 million

Aragon Pharmaceuticals, $37.7 million

Applied Proteomics, $22.5 million

Allylix, $18.2 million

SkinMedica, $16.7 million

HemaQuest Pharmaceuticals, $13 million

Genalyte, $11.8 million

PhotoThera, $11.24 million

MOGL, $10 million

Based on data from Dow Jones VentureSource, the top San Diego deals were:

Sapphire Energy, $144 million

Celladon, $43 million

Aragon Pharmaceuticals, $42 million

Luxtera, $21.7 million

Allylix, $18.2 million

Genalyte, $11.8 million

Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at bbigelow@xconomy.com or call (619) 669-8788 Follow @bvbigelow

Single Page Currently on Page: 1 2 previous page

By posting a comment, you agree to our terms and conditions.